{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T20:05:58Z","timestamp":1780517158843,"version":"3.54.1"},"reference-count":162,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:00:00Z","timestamp":1607644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Digit. Health"],"abstract":"<jats:p>Improving cancer survival rates globally requires improvements in disease detection and monitoring, with the aim of improving early diagnosis and prediction of disease relapse. Traditional means of detecting and monitoring cancers rely largely on imaging and, where possible, blood-based protein biomarkers, many of which are non-specific. Treatments are being improved by identification of inherited and acquired genomic aberrations in tumors, some of which can be targeted by newly developed therapeutic interventions. Treatment of gynecological malignancy is progressively moving toward personalized therapy, as exemplified by application of PARP-inhibition for patients with BRCA-deficient tubo-ovarian cancers, or checkpoint inhibition in patients with mismatch repair-deficient disease. However, the more recent discovery of a group of biomarkers described under the umbrella term of \u201cliquid biopsy\u201d promises significant improvement in our ability to detect and monitor cancers. The term \u201cliquid biopsy\u201d is used to describe an array of tumor-derived material found in blood plasma and other bodily fluids such as ascites, pleural fluid, saliva, and urine. It includes circulating tumors cells (CTCs), circulating nucleic acids including DNA, messenger RNA and micro RNAs, and extracellular vesicles (EVs). In this review, we discuss recent advancements in liquid biopsy for biomarker detection to help in diagnosis, prognosis, and planning of treatment of ovarian and endometrial cancer.<\/jats:p>","DOI":"10.3389\/fdgth.2020.573010","type":"journal-article","created":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T10:03:13Z","timestamp":1607680993000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Non-invasive Technology Advances in Cancer\u2014A Review of the Advances in the Liquid Biopsy for Endometrial and Ovarian Cancers"],"prefix":"10.3389","volume":"2","author":[{"given":"Mark R.","family":"Openshaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri P.","family":"McVeigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin."},{"key":"B2","article-title":"Proto-oncogenes and tumor suppressor genes","volume-title":"Molecular Cell Biology","author":"Lodish","year":"2000"},{"key":"B3","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell."},{"key":"B4","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/nrc2961","article-title":"Why do viruses cause cancer? Highlights of the first century of human tumour virology","volume":"10","author":"Moore","year":"2010","journal-title":"Nat Rev Cancer."},{"key":"B5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/emmm.201202388","article-title":"Journeys into the genome of cancer cells","volume":"5","author":"Stratton","year":"2013","journal-title":"EMBO Mol Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/ijc.29128","article-title":"Tumor genome analysis includes germline genome: are we ready for surprises?","volume":"136","author":"Catenacci","year":"2015","journal-title":"Int J Cancer."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1158\/1078-0432.CCR-13-1954","article-title":"FDA perspective on companion diagnostics: an evolving paradigm","volume":"20","author":"Mansfield","year":"2014","journal-title":"Clin Cancer Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000475529","article-title":"Tumor heterogeneity in endometrial carcinoma: practical consequences","volume":"85","author":"Gatius","year":"2018","journal-title":"Pathobiology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13058-016-0725-1","article-title":"Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification","volume":"18","author":"Allott","year":"2016","journal-title":"Breast Cancer Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nature11219","article-title":"The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers","volume":"486","author":"Diaz","year":"2012","journal-title":"Nature."},{"key":"B11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1126\/science.1253462","article-title":"Spatial and temporal diversity in genomic instability processes defines lung cancer evolution","volume":"346","author":"de Bruin","year":"2014","journal-title":"Science."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1016\/j.ejca.2009.07.016","article-title":"The challenges of organising cervical screening programmes in the 15 old member states of the European Union","volume":"45","author":"Arbyn","year":"2009","journal-title":"Eur J Cancer."},{"key":"B13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ejca.2019.12.013","article-title":"Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review","volume":"127","author":"Jansen","year":"2020","journal-title":"Eur J Cancer."},{"key":"B14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","article-title":"Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis","volume":"394","author":"Drolet","year":"2019","journal-title":"Lancet."},{"key":"B15","unstructured":"A Global Strategy for Elimination of Cervical Cancer2020"},{"key":"B16","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S0140-6736(20)30068-4","article-title":"Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries","volume":"395","author":"Brisson","year":"2020","journal-title":"Lancet."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1158\/1538-7445.AM2019-2732","article-title":"Abstract 2732: Frameshift neoantigen vaccination prevent Lynch syndrome mouse model intestinal cancer","volume":"79","author":"Gelincik","year":"2019","journal-title":"Cancer Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"12122","DOI":"10.1038\/s41598-018-30466-x","article-title":"A cancer vaccine approach for personalized treatment of Lynch Syndrome","volume":"8","author":"Majumder","year":"2018","journal-title":"Sci Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s10689-013-9662-7","article-title":"Towards a vaccine to prevent cancer in Lynch syndrome patients","volume":"12","author":"von Knebel Doeberitz","year":"2013","journal-title":"Fam Cancer."},{"key":"B20","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1089\/jwh.2018.6956","article-title":"Increased incidence of endometrial cancer following the women's health initiative: an assessment of risk factors","volume":"28","author":"Constantine","year":"2019","journal-title":"J Womens Health."},{"key":"B21","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/jnci\/djx214","article-title":"International patterns and trends in endometrial cancer incidence, 1978-2013","volume":"110","author":"Lortet-Tieulent","year":"2018","journal-title":"J Natl Cancer Inst."},{"key":"B22","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1017\/S0025727300000521","article-title":"From the \u201csilent killer\u201d to the \u201cwhispering disease\u201d: ovarian cancer and the uses of metaphor","volume":"53","author":"Jasen","year":"2009","journal-title":"Med Hist."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA."},{"key":"B24","doi-asserted-by":"publisher","first-page":"djaa030","DOI":"10.1093\/jnci\/djaa030","article-title":"Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D","volume":"28","author":"Yang","year":"2020","journal-title":"J Natl Cancer Inst."},{"key":"B25","doi-asserted-by":"publisher","first-page":"djv214","DOI":"10.1093\/jnci\/djv214","article-title":"Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer","volume":"107","author":"Ramus","year":"2015","journal-title":"J Natl Cancer Inst."},{"key":"B26","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1200\/JCO.19.01907","article-title":"Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families","volume":"38","author":"Yang","year":"2020","journal-title":"J Clin Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.pathol.2017.10.009","article-title":"Uncommon hereditary gynaecological tumour syndromes: pathological features in tumours that may predict risk for a germline mutation","volume":"50","author":"Garg","year":"2018","journal-title":"Pathology."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1136\/gutjnl-2017-314057","article-title":"Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the prospective lynch syndrome database","volume":"67","author":"M\u00f8ller","year":"2018","journal-title":"Gut."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1200\/JCO.2018.78.4777","article-title":"Cancer risks for PMS2-associated lynch syndrome","volume":"36","author":"Ten Broeke","year":"2018","journal-title":"J Clin Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1158\/1078-0432.CCR-11-2283","article-title":"Lifetime cancer risks in individuals with germline PTEN mutations","volume":"18","author":"Tan","year":"2012","journal-title":"Clin Cancer Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/gim.2015.75","article-title":"POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and\/or polyposis: review of reported cases and recommendations for genetic testing and surveillance","volume":"18","author":"Bellido","year":"2016","journal-title":"Genet Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1158\/1078-0432.CCR-1029-3","article-title":"Pathology of ovarian cancers in BRCA1 and BRCA2 carriers","volume":"10","author":"Lakhani","year":"2004","journal-title":"Clin Cancer Res."},{"key":"B33","volume-title":"Peutz-Jeghers Syndrome, in StatPearls [Internet]","author":"Wu","year":"2019"},{"key":"B34","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/cge.12917","article-title":"Genetics and genomics of ovarian sex cord-stromal tumors","volume":"91","author":"Fuller","year":"2017","journal-title":"Clin Genet."},{"key":"B35","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/00004347-199407000-00010","article-title":"Oxyphilic sertoli cell tumor of the ovary: a report of three cases, two in patients with the peutz-jeghers syndrome","volume":"13","author":"Ferry","year":"1994","journal-title":"Int J Gynecol Pathol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3892\/mco.2014.397","article-title":"Features of ovarian cancer in Lynch syndrome (Review)","volume":"2","author":"Nakamura","year":"2014","journal-title":"Mol Clin Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/107327480901600103","article-title":"Endometrial cancer and Lynch syndrome: clinical and pathologic considerations","volume":"16","author":"Meyer","year":"2009","journal-title":"Cancer Control."},{"key":"B38","doi-asserted-by":"publisher","first-page":"219012","DOI":"10.1155\/2015\/219012","article-title":"Hereditary syndromes manifesting as endometrial carcinoma: how can pathological features aid risk assessment?","volume":"2015","author":"Wong","year":"2015","journal-title":"Biomed Res Int."},{"key":"B39","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ygyno.2018.05.011","article-title":"Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation","volume":"150","author":"Kotsopoulos","year":"2018","journal-title":"Gynecol Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1136\/gutjnl-2012-304356","article-title":"Revised guidelines for the clinical management of lynch syndrome (HNPCC): recommendations by a group of European experts","volume":"62","author":"Vasen","year":"2013","journal-title":"Gut."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1038\/s41436-019-0489-y","article-title":"The manchester international consensus group recommendations for the management of gynecological cancers in lynch syndrome","volume":"21","author":"Crosbie","year":"2019","journal-title":"Genet Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.bpobgyn.2020.01.006","article-title":"Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers","volume":"65","author":"Gaba","year":"2020","journal-title":"Best Pract Res Clin Obstet Gynaecol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/cam4.2725","article-title":"The fallopian tube as origin of ovarian cancer: change of diagnostic and preventive strategies","volume":"9","author":"Kyo","year":"2020","journal-title":"Cancer Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/1471-0528.15651","article-title":"Risk-reducing early salpingectomy and delayed oophorectomy as a two-staged alternative for primary prevention of ovarian cancer in women at increased risk: a commentary","volume":"126","author":"Gaba","year":"2019","journal-title":"BJOG."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1097\/DCR.0000000000000223","article-title":"The effect of hysterectomy on colonoscopy completion: a systematic review and meta-analysis","volume":"57","author":"Clancy","year":"2014","journal-title":"Dis Colon Rectum."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.3390\/cancers12051256","article-title":"Detecting endometrial cancer by blood spectroscopy: a diagnostic cross-sectional study","volume":"12","author":"Paraskevaidi","year":"2020","journal-title":"Cancers."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1200\/JCO.2016.69.9330","article-title":"Evidence of stage shift in women diagnosed with ovarian cancer during phase ii of the united kingdom familial ovarian cancer screening study","volume":"35","author":"Rosenthal","year":"2017","journal-title":"J Clin Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/j.1471-0528.1990.tb02448.x","article-title":"A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer","volume":"97","author":"Jacobs","year":"1990","journal-title":"Br J Obstet Gynaecol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1136\/jcp.2004.018077","article-title":"The role of CA125 in clinical practice","volume":"58","author":"Moss","year":"2005","journal-title":"J Clin Pathol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7150\/jca.7810","article-title":"Current approaches and challenges in managing and monitoring treatment response in ovarian cancer","volume":"5","author":"Marcus","year":"2014","journal-title":"J Cancer."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","article-title":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial","volume":"376","author":"Rustin","year":"2010","journal-title":"Lancet."},{"key":"B52","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12014-017-9169-6","article-title":"A multiplex platform for the identification of ovarian cancer biomarkers","volume":"14","author":"Boylan","year":"2017","journal-title":"Clin Proteomics."},{"key":"B53","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/s41416-019-0718-9","article-title":"Improved early detection of ovarian cancer using longitudinal multimarker models","volume":"122","author":"Whitwell","year":"2020","journal-title":"Br J Cancer."},{"key":"B54","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1093\/annonc\/mdw142","article-title":"BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer","volume":"27","author":"Moschetta","year":"2016","journal-title":"Ann Oncol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1093\/jnci\/djy085","article-title":"Biomarkers for homologous recombination deficiency in cancer","volume":"110","author":"Hoppe","year":"2018","journal-title":"J Natl Cancer Inst."},{"key":"B57","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Levine","year":"2013","journal-title":"Nature."},{"key":"B58","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science."},{"key":"B59","doi-asserted-by":"publisher","first-page":"6847","DOI":"10.1158\/1078-0432.CCR-08-1387","article-title":"Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology","volume":"14","author":"Pal","year":"2008","journal-title":"Clin Cancer Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1002\/ijc.25835","article-title":"Frequency of mismatch repair deficiency in ovarian cancer: a systematic review","volume":"129","author":"Murphy","year":"2011","journal-title":"Int J Cancer."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e1003263","DOI":"10.1371\/journal.pmed.1003263","article-title":"The proportion of endometrial tumours associated with Lynch syndrome (PETALS): a prospective cross-sectional study","volume":"17","author":"Ryan","year":"2020","journal-title":"PLoS Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1634\/theoncologist.2016-0046","article-title":"mismatch repair deficiency and response to immune checkpoint blockade","volume":"21","author":"Lee","year":"2016","journal-title":"Oncologist."},{"key":"B63","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s12254-020-00579-z","article-title":"Current state and perspectives of checkpoint inhibitors in ovarian cancer treatment","volume":"13","author":"Bartl","year":"2020","journal-title":"Magaz Eur Med Oncol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_280503","article-title":"A review of immune checkpoint blockade therapy in endometrial cancer","volume":"40","author":"Green","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_280539","article-title":"Immune therapy opportunities in ovarian cancer","volume":"40","author":"Kandalaft","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book."},{"key":"B66","doi-asserted-by":"publisher","first-page":"6897","DOI":"10.1158\/1078-0432.CCR-04-0378","article-title":"Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases","volume":"10","author":"Allard","year":"2004","journal-title":"Clin Cancer Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/onc.2015.192","article-title":"The biology of circulating tumor cells","volume":"35","author":"Pantel","year":"2016","journal-title":"Oncogene."},{"key":"B68","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/1476-4598-13-223","article-title":"Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer","volume":"13","author":"Alonso-Alconada","year":"2014","journal-title":"Mol Cancer."},{"key":"B69","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.ccr.2013.09.007","article-title":"Origins of metastatic traits","volume":"24","author":"Vanharanta","year":"2013","journal-title":"Cancer Cell."},{"key":"B70","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nrc.2017.6","article-title":"Pre-metastatic niches: organ-specific homes for metastases","volume":"17","author":"Peinado","year":"2017","journal-title":"Nat Rev Cancer."},{"key":"B71","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/978-1-4939-7144-2_24","article-title":"Circulating tumor cells: markers and methodologies for enrichment and detection","volume":"1634","author":"Alvarez Cubero","year":"2017","journal-title":"Methods Mol Biol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nrc3820","article-title":"Challenges in circulating tumour cell research","volume":"14","author":"Alix-Panabi\u00e8res","year":"2014","journal-title":"Nat Rev Cancer."},{"key":"B73","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1158\/2159-8290.CD-15-1483","article-title":"Clinical applications of circulating tumor cells and circulating tumor dna as liquid biopsy","volume":"6","author":"Alix-Panabi\u00e8res","year":"2016","journal-title":"Cancer Discov."},{"key":"B74","doi-asserted-by":"publisher","first-page":"10939","DOI":"10.2147\/CMAR.S211455","article-title":"Circulating tumor cell detection in epithelial ovarian cancer using dual-component antibodies targeting EpCAM And FR\u03b1","volume":"11","author":"Li","year":"2019","journal-title":"Cancer Manage Res."},{"key":"B75","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1158\/1078-0432.CCR-16-0825","article-title":"Mutation analysis of cell-free DNA and single circulating tumor cells in metastatic breast cancer patients with high CTC counts","volume":"23","author":"Shaw","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.molonc.2016.04.002","article-title":"Gene expression profiling of single circulating tumor cells in ovarian cancer - establishment of a multi-marker gene panel","volume":"10","author":"Blassl","year":"2016","journal-title":"Mol Oncol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3978\/j.issn.2305-5839.2014.10.04","article-title":"Circulating tumor cells and epithelial, mesenchymal and stemness markers: characterization of cell subpopulations","volume":"2","author":"Barriere","year":"2014","journal-title":"Ann Transl Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1146\/annurev-genom-090413-025352","article-title":"Single-cell whole-genome amplification and sequencing: methodology and applications","volume":"16","author":"Huang","year":"2015","journal-title":"Annu Rev Genomics Hum Genet."},{"key":"B79","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41568-019-0180-2","article-title":"Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells","volume":"19","author":"Keller","year":"2019","journal-title":"Nat Rev Cancer."},{"key":"B80","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/nbt.2282","article-title":"Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells","volume":"30","author":"Ramsk\u00f6ld","year":"2012","journal-title":"Nat Biotechnol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"9761","DOI":"10.1021\/acs.analchem.5b01901","article-title":"Single-cell codetection of metabolic activity, intracellular functional proteins, and genetic mutations from rare circulating tumor cells","volume":"87","author":"Zhang","year":"2015","journal-title":"Anal Chem."},{"key":"B82","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4137\/BMI.S35075","article-title":"Isolation of circulating tumor cells from multiple epithelial cancers with apostream(\u00ae) for detecting (or monitoring) the expression of folate receptor alpha","volume":"11","author":"O'Shannessy","year":"2016","journal-title":"Biomarker insights."},{"key":"B83","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.canlet.2019.10.014","article-title":"Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: ready for prime time?","volume":"468","author":"Asante","year":"2020","journal-title":"Cancer Letters."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s00404-020-05477-7","article-title":"Clinical relevance of circulating tumor cells in ovarian, fallopian tube and peritoneal cancer","volume":"301","author":"Banys-Paluchowski","year":"2020","journal-title":"Arch Gynecol Obstet"},{"key":"B85","doi-asserted-by":"publisher","first-page":"e018884","DOI":"10.1136\/bmjopen-2017-018884","article-title":"Circulating tumour cells as a potential screening tool for lung cancer (the AIR study): protocol of a prospective multicentre cohort study in France","volume":"7","author":"Leroy","year":"2017","journal-title":"BMJ Open."},{"key":"B86","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/annonc\/mdx636","article-title":"Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer","volume":"29","author":"Ilie","year":"2018","journal-title":"Ann Oncol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/1878-0261.12113","article-title":"Molecular analysis of single circulating tumour cells following long-term storage of clinical samples","volume":"11","author":"Mesquita","year":"2017","journal-title":"Mol Oncol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s10147-017-1105-2","article-title":"Circulating tumor cells: clinical validity and utility","volume":"22","author":"Cabel","year":"2017","journal-title":"Int J Clin Oncol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.euo.2018.02.009","article-title":"Consensus statement on circulating biomarkers for advanced prostate cancer","volume":"1","author":"Sumanasuriya","year":"2018","journal-title":"Eur Urol Oncol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.ygyno.2011.05.028","article-title":"Circulating tumor cells predict progression free survival and overall survival in patients with relapsed\/recurrent advanced ovarian cancer","volume":"122","author":"Poveda","year":"2011","journal-title":"Gynecol Oncol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1097\/IGC.0000000000000459","article-title":"The predictive value of circulating tumor cells in ovarian cancer: a meta analysis","volume":"27","author":"Zeng","year":"2017","journal-title":"Int J Gynecol Cancer."},{"key":"B92","doi-asserted-by":"publisher","first-page":"106415","DOI":"10.18632\/oncotarget.22468","article-title":"Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium","volume":"8","author":"Obermayr","year":"2017","journal-title":"Oncotarget."},{"key":"B93","doi-asserted-by":"publisher","first-page":"7522","DOI":"10.18632\/oncotarget.23943","article-title":"Diagnostic value of HE4+ circulating tumor cells in patients with suspicious ovarian cancer","volume":"9","author":"Guo","year":"2018","journal-title":"Oncotarget."},{"key":"B94","unstructured":"Detection of circulating tumor cells in high-risk endometrial cancer6837\n            BoganiG\n            LiuMC\n            DowdySC\n            ClibyWA\n            KerrSE\n            KalliKR\n          25667446Anticancer Res.352015"},{"key":"B95","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.21873\/anticanres.12550","article-title":"Correlation between disease stage and the presence of viable circulating tumor cells in endometrial cancer","volume":"38","author":"Kiss","year":"2018","journal-title":"Anticancer Res."},{"key":"B96","first-page":"646","article-title":"Free DNA in the serum of cancer patients and the effect of therapy","volume":"37","author":"Leon","year":"1977","journal-title":"Cancer Res."},{"key":"B97","first-page":"67","article-title":"Soluble normal and mutated DNA sequences from single-copy genes in human blood","volume":"3","author":"Sorenson","year":"1994","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"B98","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10555-016-9629-x","article-title":"Origins, structures, and functions of circulating DNA in oncology","volume":"35","author":"Thierry","year":"2016","journal-title":"Cancer Metastasis Rev."},{"key":"B99","unstructured":"DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells165965\n            JahrS\n            HentzeH\n            EnglischS\n            HardtD\n            FackelmayerFO\n            HeschRD\n          11245480Cancer Res.612001"},{"key":"B100","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.mehy.2014.08.019","article-title":"Non-invasive pre-implantation genetic diagnosis of X-linked disorders","volume":"83","author":"Assou","year":"2014","journal-title":"Med Hypotheses."},{"key":"B101","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S0009-8981(01)00665-9","article-title":"About the possible origin and mechanism of circulating DNA apoptosis and active DNA release","volume":"313","author":"Stroun","year":"2001","journal-title":"Clin Chim Acta."},{"key":"B102","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1158\/1538-7445.AM2014-5606","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med."},{"key":"B103","doi-asserted-by":"publisher","first-page":"eaan2415","DOI":"10.1126\/scitranslmed.aan2415","article-title":"Direct detection of early-stage cancers using circulating tumor DNA","volume":"9","author":"Phallen","year":"2017","journal-title":"Sci Transl Med."},{"key":"B104","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1196\/annals.1368.042","article-title":"The importance of careful blood processing in isolation of cell-free DNA","volume":"1075","author":"Page","year":"2006","journal-title":"Ann N Y Acad Sci."},{"key":"B105","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.clinbiochem.2015.03.015","article-title":"Digital PCR analysis of circulating nucleic acids","volume":"48","author":"Hudecova","year":"2015","journal-title":"Clin Biochem."},{"key":"B106","doi-asserted-by":"publisher","first-page":"e0194630","DOI":"10.1371\/journal.pone.0194630","article-title":"Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA","volume":"13","author":"Gale","year":"2018","journal-title":"PLoS ONE."},{"key":"B107","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/mutage\/geu031","article-title":"Next-generation sequencing technologies: breaking the sound barrier of human genetics","volume":"29","author":"Bahassi el","year":"2014","journal-title":"Mutagenesis."},{"key":"B108","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1002\/cpmb.59","article-title":"Overview of next-generation sequencing technologies","volume":"122","author":"Slatko","year":"2018","journal-title":"Curr Protoc Mol Biol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/annonc\/mdu479","article-title":"Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data","volume":"26","author":"Favero","year":"2015","journal-title":"Ann Oncol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.bdq.2017.12.001","article-title":"An optimized targeted next-generation sequencing approach for sensitive detection of single nucleotide variants","volume":"15","author":"Stasik","year":"2018","journal-title":"Biomol Detect Quantif."},{"key":"B111","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat Med."},{"key":"B112","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature."},{"key":"B113","doi-asserted-by":"publisher","first-page":"7098","DOI":"10.1158\/1078-0432.CCR-19-1704","article-title":"Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma","volume":"25","author":"Maron","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B114","doi-asserted-by":"publisher","first-page":"a004648","DOI":"10.1101\/mcs.a004648","article-title":"Rapid development and use of patient-specific ctDNA biomarkers to avoid a \u201crash decision\u201d in an ovarian cancer patient","volume":"5","author":"Pandya","year":"2019","journal-title":"Cold Spring Harb Mol Case Stud."},{"key":"B115","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","article-title":"BRCA reversion mutations in circulating tumor dna predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma","volume":"9","author":"Lin","year":"2019","journal-title":"Cancer Discov."},{"key":"B116","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13048-017-0369-5","article-title":"Circulating cell-free DNA and circulating tumor cells, the \u201cliquid biopsies\u201d in ovarian cancer","volume":"10","author":"Cheng","year":"2017","journal-title":"J Ovarian Res."},{"key":"B117","doi-asserted-by":"publisher","first-page":"11517","DOI":"10.2147\/OTT.S227156","article-title":"Circulating cell-Free DNA or circulating tumor DNA in the management of ovarian and endometrial cancer","volume":"12","author":"Chen","year":"2019","journal-title":"Onco Targets Ther."},{"key":"B118","doi-asserted-by":"publisher","first-page":"328","DOI":"10.5468\/ogs.2018.61.3.328","article-title":"Optimization to detect TP53 mutations in circulating cell-free tumor DNA from patients with serous epithelial ovarian cancer","volume":"61","author":"Park","year":"2018","journal-title":"Obstet Gynecol Sci."},{"key":"B119","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.ajog.2005.01.054","article-title":"Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer","volume":"193","author":"Swisher","year":"2005","journal-title":"Am J Obstet Gynecol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"e1002198","DOI":"10.1371\/journal.pmed.1002198","article-title":"Exploratory analysis of tp53 mutations in circulating tumour dna as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study","volume":"13","author":"Parkinson","year":"2016","journal-title":"PLoS Med."},{"key":"B121","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1158\/1078-0432.CCR-16-1078","article-title":"Chromosomal instability in cell-free DNA as a highly specific biomarker for detection of ovarian cancer in women with adnexal masses","volume":"23","author":"Vanderstichele","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B122","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/ijc.25077","article-title":"Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancer","volume":"127","author":"Dobrzycka","year":"2010","journal-title":"Int J Cancer."},{"key":"B123","doi-asserted-by":"publisher","first-page":"e0145754","DOI":"10.1371\/journal.pone.0145754","article-title":"Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers","volume":"10","author":"Pereira","year":"2015","journal-title":"PLoS ONE."},{"key":"B124","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41379-018-0158-8","article-title":"Targeted next-generation sequencing of endometrial cancer and matched circulating tumor DNA: identification of plasma-based, tumor-associated mutations in early stage patients","volume":"32","author":"Bolivar","year":"2019","journal-title":"Mod Pathol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"114","DOI":"10.14694\/EdBook_AM.2015.35.114","article-title":"Chemotherapy for patients with BRCA1 and BRCA2-mutated ovarian cancer: same or different?","volume":"2015","author":"Tan","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book."},{"key":"B126","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1200\/JCO.2016.70.4627","article-title":"Reversion of BRCA1\/2 germline mutations detected in circulating tumor dna from patients with high-grade serous ovarian cancer","volume":"35","author":"Christie","year":"2017","journal-title":"J Clin Oncol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1126\/science.aar3247","article-title":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","volume":"359","author":"Cohen","year":"2018","journal-title":"Science."},{"key":"B129","doi-asserted-by":"publisher","first-page":"eaap8793","DOI":"10.1126\/scitranslmed.aap8793","article-title":"Evaluation of liquid from the papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers","volume":"10","author":"Wang","year":"2018","journal-title":"Sci Transl Med."},{"key":"B130","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/0092-8674(93)90529-Y","article-title":"The elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14","volume":"75","author":"Lee","year":"1993","journal-title":"Cell."},{"key":"B131","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrm3611","article-title":"Diversifying microRNA sequence and function","volume":"14","author":"Ameres","year":"2013","journal-title":"Nat Rev Mol Cell Biol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1101\/gr.082701.108","article-title":"Most mammalian mRNAs are conserved targets of microRNAs","volume":"19","author":"Friedman","year":"2009","journal-title":"Genome Res."},{"key":"B133","doi-asserted-by":"publisher","first-page":"5003","DOI":"10.1073\/pnas.1019055108","article-title":"Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma","volume":"108","author":"Arroyo","year":"2011","journal-title":"Proc Natl Acad Sci USA."},{"key":"B134","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1038\/ncomms4292","article-title":"HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells","volume":"5","author":"Tabet","year":"2014","journal-title":"Nat Commun."},{"key":"B135","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/bs.acr.2017.06.002","article-title":"Cancer hallmarks and microRNAs: the therapeutic connection","volume":"135","author":"Van Roosbroeck","year":"2017","journal-title":"Adv Cancer Res."},{"key":"B136","doi-asserted-by":"publisher","first-page":"10513","DOI":"10.1073\/pnas.0804549105","article-title":"Circulating microRNAs as stable blood-based markers for cancer detection","volume":"105","author":"Mitchell","year":"2008","journal-title":"Proc Natl Acad Sci USA."},{"key":"B137","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1080\/15476286.2017.1403003","article-title":"A comprehensive profile of circulating RNAs in human serum","volume":"15","author":"Umu","year":"2018","journal-title":"RNA Biol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-016-0536-0","article-title":"Clinical relevance of circulating cell-free microRNAs in ovarian cancer","volume":"15","author":"Nakamura","year":"2016","journal-title":"Mol Cancer."},{"key":"B139","doi-asserted-by":"publisher","first-page":"e0184094","DOI":"10.1371\/journal.pone.0184094","article-title":"Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer","volume":"12","author":"Souza","year":"2017","journal-title":"PLoS ONE."},{"key":"B140","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13148-018-0492-1","article-title":"Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage","volume":"10","author":"Wang","year":"2018","journal-title":"Clin Epigenetics."},{"key":"B141","doi-asserted-by":"publisher","first-page":"e77853","DOI":"10.1371\/journal.pone.0077853","article-title":"Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer","volume":"8","author":"Zheng","year":"2013","journal-title":"PLoS ONE."},{"key":"B142","doi-asserted-by":"publisher","first-page":"e110767","DOI":"10.1371\/journal.pone.0110767","article-title":"Circulating microRNAs as a fingerprint for endometrial endometrioid adenocarcinoma","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS ONE."},{"key":"B143","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.trsl.2018.10.003","article-title":"Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes","volume":"205","author":"Giannopoulou","year":"2019","journal-title":"Transl Res."},{"key":"B144","unstructured":"Circulating messenger rna profiling with microarray and next-generation sequencing: cross-platform comparison22330\n            ShihCL\n            LuoJD\n            ChangJW\n            ChenTL\n            ChienYT\n            YuCJ\n          26417025Cancer Genomics Proteomics.122015"},{"key":"B145","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nrd3978","article-title":"Extracellular vesicles: biology and emerging therapeutic opportunities","volume":"12","author":"EL Andaloussi","year":"2013","journal-title":"Nat Rev Drug Discov."},{"key":"B146","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/ncb1596","article-title":"Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells","volume":"9","author":"Valadi","year":"2007","journal-title":"Nat Cell Biol."},{"key":"B147","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.semcdb.2015.02.009","article-title":"Exosomes and their roles in immune regulation and cancer","volume":"40","author":"Greening","year":"2015","journal-title":"Semin Cell Dev Biol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1038\/s41467-018-05077-9","article-title":"Priming of dendritic cells by DNA-containing extracellular vesicles from activated T cells through antigen-driven contacts","volume":"9","author":"Torralba","year":"2018","journal-title":"Nat Commun."},{"key":"B149","doi-asserted-by":"publisher","first-page":"R125","DOI":"10.1093\/hmg\/dds317","article-title":"Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy","volume":"21","author":"Lee","year":"2012","journal-title":"Hum Mol Genet."},{"key":"B150","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1038\/ncb1800","article-title":"Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers","volume":"10","author":"Skog","year":"2008","journal-title":"Nat Cell Biol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1186\/s12885-017-3737-z","article-title":"Detection of circulating miRNAs: comparative analysis of extracellular vesicle-incorporated miRNAs and cell-free miRNAs in whole plasma of prostate cancer patients","volume":"17","author":"Endzelins","year":"2017","journal-title":"BMC Cancer."},{"key":"B152","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1159\/000479998","article-title":"Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth through hedgehog signaling pathway","volume":"42","author":"Qi","year":"2017","journal-title":"Cell Physiol Biochem."},{"key":"B153","doi-asserted-by":"publisher","first-page":"23736","DOI":"10.1002\/jcp.28941","article-title":"Exosomes from human-bone-marrow-derived mesenchymal stem cells protect against renal ischemia\/reperfusion injury via transferring miR-199a-3p","volume":"234","author":"Zhu","year":"2019","journal-title":"J Cell Physiol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.3390\/cancers11122000","article-title":"Extracellular vesicles-based biomarkers represent a promising liquid biopsy in endometrial cancer","volume":"11","author":"Herrero","year":"2019","journal-title":"Cancers."},{"key":"B155","doi-asserted-by":"publisher","first-page":"C29","DOI":"10.1152\/ajpcell.00280.2019","article-title":"Extracellular vesicles as biomarkers and therapeutic targets for cancer","volume":"318","author":"Urabe","year":"2020","journal-title":"Am J Physiol Cell Physiol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1080\/14737159.2018.1544494","article-title":"The potential of tumor-derived exosomes for noninvasive cancer monitoring: an update","volume":"18","author":"Whiteside","year":"2018","journal-title":"Expert Rev Mol Diagn."},{"key":"B157","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12943-017-0706-8","article-title":"Role of exosomal proteins in cancer diagnosis","volume":"16","author":"Li","year":"2017","journal-title":"Mol Cancer."},{"key":"B158","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13048-018-0477-x","article-title":"Upregulated expression of serum exosomal miR-375 and miR-1307 enhance the diagnostic power of CA125 for ovarian cancer","volume":"12","author":"Su","year":"2019","journal-title":"J Ovarian Res."},{"key":"B159","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1038\/s41467-018-04695-7","article-title":"Soluble E-cadherin promotes tumor angiogenesis and localizes to exosome surface","volume":"9","author":"Tang","year":"2018","journal-title":"Nat Commun."},{"key":"B160","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1158\/1541-7786.MCR-16-0191","article-title":"Exosomes promote ovarian cancer cell invasion through transfer of cd44 to peritoneal mesothelial cells","volume":"15","author":"Nakamura","year":"2017","journal-title":"Mol Cancer Res."},{"key":"B161","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1158\/2326-6066.CIR-17-0479","article-title":"Exosomes released from tumor-associated macrophages transfer mirnas that induce a Treg\/Th17 cell imbalance in epithelial ovarian cancer","volume":"6","author":"Zhou","year":"2018","journal-title":"Cancer Immunol Res."},{"key":"B162","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/jnci\/djt095","article-title":"Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE","volume":"105","author":"Mavaddat","year":"2013","journal-title":"J Natl Cancer Inst."}],"container-title":["Frontiers in Digital Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdgth.2020.573010\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T10:04:06Z","timestamp":1607681046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdgth.2020.573010\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,11]]},"references-count":162,"alternative-id":["10.3389\/fdgth.2020.573010"],"URL":"https:\/\/doi.org\/10.3389\/fdgth.2020.573010","relation":{},"ISSN":["2673-253X"],"issn-type":[{"value":"2673-253X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,11]]},"article-number":"573010"}}